CoChat
Sign Up
Cited by 27

The DOI matches its Crossref record.

Biomimetic Magnetic Nanocarriers Drive Choline Kinase Alpha Inhibitor inside Cancer Cells for Combined Chemo-Hyperthermia Therapy

Jabalera, Ylenia, Sola-Leyva, Alberto, Peigneux, Ana, Vurro, Federica, Iglesias, Guillermo R., Vilchez-Garcia, Jesus, Pérez-Prieto, Inmaculada, Aguilar-Troyano, Francisco J., López-Cara, Luisa C., Carrasco-Jiménez, María P., Jimenez-Lopez, Concepcion·2019·Pharmaceutics
DOI 10.3390/pharmaceutics11080408PMC PMC6722936
Open this paper in CoChat — free account

Abstract

Choline kinase α1 (ChoKα1) has become an excellent antitumor target. Among all the inhibitors synthetized, the new compound Ff35 shows an excellent capacity to inhibit ChoKα1 activity. However, soluble Ff35 is also capable of inhibiting choline uptake, making the inhibitor not selective for ChoKα1. In this study, we designed a new protocol with the aim of disentangling whether the Ff35 biological action is due to the inhibition of the enzyme and/or to the choline uptake. Moreover, we offer an alternative to avoid the inhibition of choline uptake caused by Ff35, since the coupling of Ff35 to novel biomimetic magnetic nanoparticles (BMNPs) allows it to enter the cell through endocytosis without interacting with the choline transporter. This opens the possibility of a clinical use of Ff35. Our results indicate that Ff35-BMNPs nanoassemblies increase the selectivity of Ff35 and have an antiproliferative effect. Also, we demonstrate the effectiveness of the tandem Ff35-BMNPs and hyperthermia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/pharmaceutics11080408

Cites

Statistics

Figures

Figure 1 Chemical structure of choline kinase α 1 (ChoKα1) inhibitor Ff35.
Figure 1 Chemical structure of choline kinase α 1 (ChoKα1) inhibitor Ff35.CC BY · PubMed Central
Figure 2 Biomimetic magnetic nanoparticles (BMNPs) characterization. (A) TEM image of BMNPs and (B) crystal size distribution. (C) Hysteresis cycle of BMNPs at 300 K and 5 K. (D) Detail of the hysteresis cycle in the absence of external magnetic field at 300 K and 5 K. (E) Zero field cooling-field cooling (ZFC-FC) curves of BMNPs.
Figure 2 Biomimetic magnetic nanoparticles (BMNPs) characterization. (A) TEM image of BMNPs and (B) crystal size distribution. (C) Hysteresis cycle of BMNPs at 300 K and 5 K. (D) Detail of the hysteresis cycle in the absence of external magnetic field at 300 K and 5 K. (E) Zero field cooling-field cooling (ZFC-FC) curves of BMNPs.CC BY · PubMed Central
Figure 3 Adsorption kinetics (A) and adsorption isotherm (B) of Ff35 on BMNPs. The line represents the nonlineal weighted least-squares (NWLS) fitting of the experimental data according to LF model. In the case of adsorption kinetics, the vertical error bars are smaller than the symbol.
Figure 3 Adsorption kinetics (A) and adsorption isotherm (B) of Ff35 on BMNPs. The line represents the nonlineal weighted least-squares (NWLS) fitting of the experimental data according to LF model. In the case of adsorption kinetics, the vertical error bars are smaller than the symbol.CC BY · PubMed Central
Figure 4 Effects of Ff35, BMNPs, and Ff35-BMNPs on HepG2 cell proliferation. HepG2 cells growing in the log phase were incubated with Minimum Essential Medium containing 10% heat-inactivated fetal bovine serum (MEM/10% FBS) in the presence or absence of Ff35 up to 10 μM (A) or Ff35 1 μM, BMNPs 300 µg mL−1 or Ff35-BMNPs (concentration of Ff35 was 1 μM and that of BMNPs was 300 µg mL−1) (B). Cell viability was determined by MTT assay and normalized to that of the respective control cells. These experiments were performed twice in triplicate. * p < 0.05, ** p < 0.001 compared to their respective controls.
Figure 4 Effects of Ff35, BMNPs, and Ff35-BMNPs on HepG2 cell proliferation. HepG2 cells growing in the log phase were incubated with Minimum Essential Medium containing 10% heat-inactivated fetal bovine serum (MEM/10% FBS) in the presence or absence of Ff35 up to 10 μM (A) or Ff35 1 μM, BMNPs 300 µg mL−1 or Ff35-BMNPs (concentration of Ff35 was 1 μM and that of BMNPs was 300 µg mL−1) (B). Cell viability was determined by MTT assay and normalized to that of the respective control cells. These experiments were performed twice in triplicate. * p < 0.05, ** p < 0.001 compared to their respective controls.CC BY · PubMed Central
Figure 5 (A) Effects of Ff35 on ChoKα1 activity assayed in purified ChoKα1 exposed to different Ff35 concentrations. The results are expressed as percentage of enzymatic inhibition. (B) Choline uptake assay in HepG2 cells. Choline uptake was determined in cells treated for 10 min, 24 h, and 48 h soluble Ff35 or Ff35-BMNPs. Results are normalized to their respective control. These experiments were performed three times in triplicates. * p < 0.05, ** p < 0.001 compared to their respective controls.
Figure 5 (A) Effects of Ff35 on ChoKα1 activity assayed in purified ChoKα1 exposed to different Ff35 concentrations. The results are expressed as percentage of enzymatic inhibition. (B) Choline uptake assay in HepG2 cells. Choline uptake was determined in cells treated for 10 min, 24 h, and 48 h soluble Ff35 or Ff35-BMNPs. Results are normalized to their respective control. These experiments were performed three times in triplicates. * p < 0.05, ** p < 0.001 compared to their respective controls.CC BY · PubMed Central
Figure 6 Internalization of BMNPs and Ff35-BMNPs. Ultrastructural alterations produced by Ff35-BMNPs. (A,B): Control HepG2 cells. (C,D): HepG2 cell exposed to BMNPs has ultrastructure similar to control cells. (E,F): Treatment with Ff35-BMNPs (concentration of BMNPs was 300 µg mL−1 and Ff35 was 1 μM). Perinuclear space (Ps) is visible. The two nuclear membranes were separated showing a dilatation of the Ps. It is notably mitochondrial (M) rarefaction, disorganization, and dilatation. Both BMNPs and Ff35-BMNPs were internalized by HepG2 cells via endocytosis and compartmentalized in endosomes (Ed). Scale bar corresponds to 2 µm (A,C,E) and 1 µm (B,D,F).
Figure 6 Internalization of BMNPs and Ff35-BMNPs. Ultrastructural alterations produced by Ff35-BMNPs. (A,B): Control HepG2 cells. (C,D): HepG2 cell exposed to BMNPs has ultrastructure similar to control cells. (E,F): Treatment with Ff35-BMNPs (concentration of BMNPs was 300 µg mL−1 and Ff35 was 1 μM). Perinuclear space (Ps) is visible. The two nuclear membranes were separated showing a dilatation of the Ps. It is notably mitochondrial (M) rarefaction, disorganization, and dilatation. Both BMNPs and Ff35-BMNPs were internalized by HepG2 cells via endocytosis and compartmentalized in endosomes (Ed). Scale bar corresponds to 2 µm (A,C,E) and 1 µm (B,D,F).CC BY · PubMed Central
Figure 7 Effects of Ff35-BMNPs and hyperthermia on cell proliferation in HepG2 cells. HepG2 cells growing in log-phase were incubated with MEM/10% FBS in the absence or presence Ff35-BMNPs (concentration of Ff35 was 1 μM and BMNPs was 300 µg mL−1) for 24 h, and exposed to an alternative magnetic field for 1, 2, or 3 h. Cell number was determined by the MTT assay and expressed as percentage of control cells. Percentage of viability is normalized to that for the control cells. Results represent the mean ± SEM of three independent experiments conducted in triplicate. ** p < 0.001, when compared with their respective control values.
Figure 7 Effects of Ff35-BMNPs and hyperthermia on cell proliferation in HepG2 cells. HepG2 cells growing in log-phase were incubated with MEM/10% FBS in the absence or presence Ff35-BMNPs (concentration of Ff35 was 1 μM and BMNPs was 300 µg mL−1) for 24 h, and exposed to an alternative magnetic field for 1, 2, or 3 h. Cell number was determined by the MTT assay and expressed as percentage of control cells. Percentage of viability is normalized to that for the control cells. Results represent the mean ± SEM of three independent experiments conducted in triplicate. ** p < 0.001, when compared with their respective control values.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 28

  1. Siegel, 2018, Cancer statistics, 2018, CA Cancer J. Clin., 68, 7, 10.3322/caac.21442 · DOI
  2. Hanahan, 2000, The Hallmarks of Cancer, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9 · DOI · Paper page
  3. Huang, 2015, Lipid metabolism, apoptosis and cancer therapy, Int. J. Mol. Sci., 16, 924, 10.3390/ijms16010924 · DOI
  4. Galbraith, 2018, Lipid pathway deregulation in advanced prostate cancer, Pharmacol. Res., 131, 177, 10.1016/j.phrs.2018.02.022 · DOI
  5. Glunde, 2011, Choline metabolism in malignant transformation, Nat. Rev. Cancer, 11, 835, 10.1038/nrc3162 · DOI
  6. Cao, 2016, Targeting choline phospholipid metabolism: GDPD5 and GDPD6 silencing decrease breast cancer cell proliferation, migration, and invasion, NMR Biomed., 29, 1098, 10.1002/nbm.3573 · DOI
  7. Iorio, 2016, Key Players in Choline Metabolic Reprograming in Triple-Negative Breast Cancer, Front. Oncol., 6, 205, 10.3389/fonc.2016.00205 · DOI
  8. Kennelly, 2017, The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease, Biochim. Biophys. Acta Biomembr., 1859, 1558, 10.1016/j.bbamem.2017.04.006 · DOI · Paper page
  9. Yalcin, 2010, Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling, Oncogene, 29, 139, 10.1038/onc.2009.317 · DOI
  10. Mori, 2007, Choline Kinase Down-regulation Increases the Effect of 5-Fluorouracil in Breast Cancer Cells, Cancer Res., 67, 11284, 10.1158/0008-5472.CAN-07-2728 · DOI
  11. Chen, Z., Krishnamachary, B., and Bhujwalla, Z. (2016). Degradable Dextran Nanopolymer as a Carrier for Choline Kinase (ChoK) siRNA Cancer Therapy. Nanomaterials, 6. · DOI
  12. Baglioni, 2016, Design, synthesis, crystallization and biological evaluation of new symmetrical biscationic compounds as selective inhibitors of human Choline Kinase α1 (ChoKα1), Sci. Rep., 6, 23793, 10.1038/srep23793 · DOI
  13. Arlauckas, 2016, Choline kinase alpha—Putting the ChoK-hold on tumor metabolism, Prog. Lipid Res., 63, 28, 10.1016/j.plipres.2016.03.005 · DOI
  14. Lacal, 2015, Choline kinase as a precision medicine target for therapy in cancer, autoimmune diseases and malaria, Precis. Med., 2, 980
  15. Bioisoterism, 2017, Review-An Biological Modification, World J. Pharm. Pharm. Sci., 6, 1918
  16. Marco, 2019, Choline kinase inhibitors EB-3D and EB-3P interferes with lipid homeostasis in HepG2 cells, Sci. Rep., 9, 5109, 10.1038/s41598-019-40885-z · DOI
  17. Prozorov, 2013, Novel magnetic nanomaterials inspired by magnetotactic bacteria: Topical review, Mater. Sci. Eng. R Rep., 74, 133, 10.1016/j.mser.2013.04.002 · DOI · Paper page
  18. Peigneux, 2018, pH-Dependent Adsorption Release of Doxorubicin on MamC-Biomimetic Magnetite Nanoparticles, Langmuir, 34, 13713, 10.1021/acs.langmuir.8b03109 · DOI · Paper page
  19. Prozorov, 2015, Size control of In Vitro synthesized magnetite crystals by the MamC protein of Magnetococcus marinus strain MC-1, Appl. Microbiol. Biotechnol., 99, 5109, 10.1007/s00253-014-6326-y · DOI · Paper page
  20. 2010, Inorganic Magnetite Precipitation at 25 °C: A Low-Cost Inorganic Coprecipitation Method, J. Supercond. Nov. Magn., 24, 549
  21. Turiel, 2003, Assessment of the cross-reactivity and binding sites characterisation of a propazine-imprinted polymer using the Langmuir-Freundlich isotherm, Analyst, 128, 137, 10.1039/b210712k · DOI
  22. Carrasco, 2002, Hexadecylphosphocholine inhibits phosphatidylcholine biosynthesis and the proliferation of HepG2 cells, Eur. J. Biochem., 269, 4649, 10.1046/j.1432-1033.2002.03169.x · DOI
  23. Reynolds, 1963, The use of lead citrate at high pH as an electron-opaque stain in electron microscopy, J. Cell Biol., 17, 208, 10.1083/jcb.17.1.208 · DOI
  24. Iafisco, 2016, Superparamagnetic iron-doped nanocrystalline apatite as a delivery system for doxorubicin, J. Mater. Chem. B, 4, 57, 10.1039/C5TB01524C · DOI
  25. Geisow, 1984, pH in the endosome. Measurements during pinocytosis and receptor-mediated endocytosis, Exp. Cell Res., 150, 36, 10.1016/0014-4827(84)90699-2 · DOI
  26. Skowronek, 2007, Hyperthermia–description of a method and a review of clinical applications, Rep. Pract. Oncol. Radiother., 12, 267, 10.1016/S1507-1367(10)60065-X · DOI
  27. Lim, 2006, Cell cycle dependent apoptosis and cell cycle blocks induced by hyperthermia in HL-60 cells, Int. J. Hyperth., 22, 77, 10.1080/02656730500430538 · DOI
  28. Iglesias, G.R., Reyes-Ortega, F., Fernandez, B.L.C., and Delgado, Á.V. (2018). Hyperthermia-triggered gemcitabine release from polymer-coated magnetite nanoparticles. Polymers, 10. · DOI

Cited by

Sorted by citations

See all 27

Metadata

Authors
Jabalera, Y., Sola-Leyva, A., Peigneux, A., Vurro, F., Iglesias, G. R., Vilchez-Garcia, J., Pérez-Prieto, I., Aguilar-Troyano, F. J., López-Cara, L. C., Carrasco-Jiménez, M. P., & Jimenez-Lopez, C.
Venue
Pharmaceutics
Publisher
MDPI AG
Published
2019-08-12
Volume
11
Issue
8
Pages
408
ISSN
1999-4923
DOI
10.3390/pharmaceutics11080408
PMC
PMC6722936
Cited by
27
References
0
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
  • Ministerio de Economía y Competitividad (CGL2013-46612, CGL2016-76723)
  • Ramón y Cajal Programme (RYC-2014-16901)
  • Andalusian regional government (CTS-236)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Biomimetic Magnetic Nanocarriers Drive Choline Kinase Alpha Inhibitor inside Cancer Cells for Combined Chemo-Hyperthermia Therapy. https://app.cochat.ai/papers/10.3390/pharmaceutics11080408
The paper
Jabalera, Y., Sola-Leyva, A., Peigneux, A., Vurro, F., Iglesias, G. R., Vilchez-Garcia, J., Pérez-Prieto, I., Aguilar-Troyano, F. J., López-Cara, L. C., Carrasco-Jiménez, M. P., & Jimenez-Lopez, C. (2019). Biomimetic Magnetic Nanocarriers Drive Choline Kinase Alpha Inhibitor inside Cancer Cells for Combined Chemo-Hyperthermia Therapy. Pharmaceutics. https://doi.org/10.3390/pharmaceutics11080408